Connect with us

Market

Sorrento Therapeutics Inc (NASDAQ: SRNE): Members Made A Hefty 15% Profit In 24 Hours

Published

on

Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here http://tradersinsights.com/pricing/

 JOIN US NOW: For Details Contact us at info@tradersinsights.com

 Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy Sorrento Therapeutics Inc (NASDAQ: SRNE) yesterday (march 18th) at $2.67. Now look at the price of the stock – its up 15% at $3.23 from our buy price. This is how easy money they made. If you had invested $5,000 in SRNE, it could had been moved up to $5,750.  It’s not yet late, join us at info@tradersinsights.com

Continue Reading

Market

ConforMIS Inc (NASDAQ: CFMS): Premium Members Made A Quick 65% Profit In Just 1 week

Published

on

Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here http://tradersinsights.com/pricing/
JOIN US NOW: For Details Contact us at info@tradersinsights.com

Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy ConforMIS Inc (NASDAQ: CFMS) yesterday (march 13th) at $1.36. Now look at the price of the stock – its up 65% at $2.25 from our buy price. This is how easy money they made. If you had invested $5,000 in CFMS, it could had been moved up to $8,250. It’s not yet late, join us at info@tradersinsights.com

Continue Reading

Market

Rockwell Medical Inc (NASDAQ: RMTI): Premium Members Made A Quick 20% Profit In 24 Hours

Published

on

Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here http://tradersinsights.com/pricing/
JOIN US NOW: For Details Contact us at info@tradersinsights.com

Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy Rockwell Medical Inc (NASDAQ: RMTI) yesterday (march 18th) at $5.42. Now look at the price of the stock – its up 20% at $6.55 from our buy price. This is how easy money they made. If you had invested $5,000 in RMTI, it could had been moved up to $6,000. It’s not yet late, join us at info@tradersinsights.com

Continue Reading

Market

BioPharmX (BPMX), Verona Pharma plc (VRNA) Are Top Biotech Stock Movers

Published

on

BioPharmX (BPMX) has completed enrollment of 207 subjects in a Phase 2b clinical trial evaluating topical minocycline gel BPX-04 in patients with moderate-to-severe papulopustular rosacea, a skin condition characterized by acne-like breakouts.

The randomized study will assess the safety and effectiveness of once-daily BPX-04 over a 12-week treatment period. The primary endpoint is the mean change in the number of facial inflammatory lesions from baseline at week 12.

Why Investors Are Calling ASDN the AMZN of the Sky!

Ultra-thinly traded Verona Pharma plc (VRNA) is up 5% on triple normal volume, albeit on turnover of only 24K shares, on the heels of encouraging preliminary data from the first part of a two-part Phase 2 clinical trial evaluating a dry powder inhaler (DPI) formulation of ensifentrine (RPL554) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

Patients receiving a single dose of one of five strengths of ensifentrine DPI showed statistically significant and clinically meaningful increases in lung function versus placebo as measured by forced expiratory volume in one second (FEV1) (the amount the patient can exhale in one second).

The second part of the study assessing the candidate for one week of twice-daily doses is next up. Participants will be randomized to receive one of four dose levels or placebo. The primary endpoint will again be peak FEV1 levels.

Ensifentrine is a bronchodilator that inhibits two enzymes called phosphodiesterase 3 and 4. It is also being developed to treat cystic fibrosis and asthma.

Have you seen the article Forbes wrote about the ASDN Flying Passenger Drone and its technology?

Continue Reading
Advertisement

Trending